FluGen, which has been working with research from UW-Madison for years on developing a universal flu vaccine — one that wouldn’t have to be updated each year, as the flu shot is now — is incorporating a coronavirus vaccine into its plans, though president and CEO Paul Radspinner said there is no timeline for getting the vaccine to human studies as of yet.
Office of Strategic Communication